Management of Perioperative Coagulopathies

Preoperative Management

Identification of Bleeding Risk

• A structured bleeding history should be obtained using standardized questions about prior surgical bleeding, dental bleeding, menorrhagia, and family history.¹
• Medication review must include anticoagulants, antiplatelet drugs, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors, herbal agents (e.g., ginkgo, garlic, ginseng), and chemotherapeutics.² (Link)
• Comorbidities such as liver disease, renal failure, sepsis, myeloproliferative disorders, and malnutrition should be recognized because they reflect underlying impairments in coagulation factor synthesis, platelet count, or platelet function.^1,8

Preoperative Laboratory Assessment and Decision Thresholds

• Selective laboratory evaluation should include complete blood cell count, prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR), fibrinogen, and renal and hepatic panels in patients with relevant risk factors.¹ (Link)
• Platelet count should be optimized to greater than 50 × 10⁹/L for most surgical procedures and greater than 100 × 10⁹/L for neurosurgical or ocular cases, since higher thresholds are needed in confined spaces where hematoma formation carries severe morbidity.⁴
• Fibrinogen should be maintained greater than 150 mg/L for major non-obstetric surgery and greater than 200 mg/L in obstetrics.^1,5
• Factor XIII levels should be checked in high-risk cases, if available, because FXIII levels less than 30% are associated with unstable clots that appear to form normally but degrade prematurely, contributing to diffuse oozing and prolonged drainage output.³
• Viscoelastic testing (TEG) should be performed in anticipated high-blood-loss cases because these assays provide functional data on clot initiation, clot firmness, and fibrinolysis and reveal defects not apparent on standard laboratory tests.^5,6 (Link)
• In patients with renal dysfunction or those taking direct oral anticoagulants (DOACs), creatinine clearance and drug timing should be reviewed, as impaired renal function prolongs drug clearance and levels residual anticoagulant activity at the time of surgery.²

Preoperative Anemia and Iron Optimization

• Hemoglobin should be optimized to above 13 mg/dL for elective major surgery since preoperative anemia increases transfusion requirements and exacerbates coagulopathy through hypoperfusion-driven acidosis.¹ (Link)
• Ideally, iron deficiency should be corrected with IV iron when surgery is imminent (<4 weeks).¹
• In cases of chronic kidney disease, erythropoiesis-stimulating agents may be used several weeks in advance.¹

Preoperative Management of Antithrombotic Drugs

• Warfarin should be discontinued 5 days before surgery and reversed with 4-factor prothrombin complex concentrate (PCC) plus vitamin K when urgent correction is required.² (Link)
• DOACs should generally be held for 2-3 days in patients with normal renal function and longer in renal impairment.²
• Emergency reversal of DOACs may require adexanet alfa (for Xa inhibitors) or idarucizumab (for dabigatran).²
• Aspirin may be continued for most nonneurosurgical operations because its continuation rarely increases the risk of major bleeding. In contrast, premature cessation of P2Y₁₂ inhibitors in patients with recent coronary stenting may precipitate stent thrombosis and myocardial infarction.² (Link)

Intraoperative Management

Vascular Access, Monitoring

• Patients with substantial bleeding risk should receive at least two 16- or 14-gauge IVs or a high-flow central venous catheter, because rapid transfusion and vasopressor administration require high-capacity access.¹
• An arterial line should be placed when significant bleeding or vasoactive drug administration is anticipated, as continuous beat-to-beat monitoring enables rapid intervention for hemodynamic instability.¹
• Point-of-care testing access (blood gas, hemoglobin, electrolytes, ionized calcium) should be readily available to facilitate rapid correction of physiological derangements.¹

Prevention of the Hemostatic “Lethal Triad”

• Core temperature should be maintained ≥36°C through forced-air warming, fluid warmers, and minimizing exposure, because hypothermia slows enzymatic reactions in the coagulation cascade and reduces platelet function.¹
• pH should be maintained above 7.30 by avoiding excessive normal saline, prioritizing hemorrhage control, and supporting blood pressure with balanced transfusion and vasopressors, because acidosis impairs thrombin generation and weakens fibrin polymerization.¹
• Ionized calcium should be checked every 30-60 minutes during moderate to severe hemorrhage and maintained above 1.1 mmol/L, as citrate-containing blood products rapidly deplete calcium and impair cardiac function and coagulation.¹⁰

Volume and Hemodynamic Strategy

• Mean arterial pressure should be maintained above 65 mmHg with vasopressors, as needed, to ensure adequate tissue oxygenation and endogenous factor synthesis.¹
• Crystalloid infusion should be minimized and replaced with balanced component therapy, as excessive crystalloid dilutes platelets and clotting factors, increases intensive care unit (ICU) length of stay, and worsens edema.¹
• Balanced transfusion using red blood cells (RBCs), plasma, and platelets should be initiated early in uncontrolled hemorrhage to prevent dilutional coagulopathy and maintain oxygen delivery.¹

Goal-Directed Component Therapy

• RBCs should be transfused to maintain hemoglobin above 7 mg/dL for most patients and above 8-9 mg/dL for those with ischemic heart disease, because inadequate oxygen delivery promotes lactic acidosis and coagulopathy.⁹ (Link)
• Platelets should be transfused to maintain platelet counts greater than 50 x 109/L or greater than 100 x 109/L for neurosurgery or ocular procedures.⁴
• Fibrinogen replacement should be administered when levels fall below the threshold, using cryoprecipitate or fibrinogen concentrate; typical dosing is 2-4 g of fibrinogen concentrate or 10 units of cryoprecipitate to raise fibrinogen by 100 mg/dL.⁵ (Link)
• Factor XIII concentrate (typically 15-20 units/kg) should be considered when FXIII deficiency is documented or suspected, because FXIII strengthens fibrin cross-linking and reduces late bleeding.¹ Link

Viscoelastic-Guided Transfusion

• When viscoelastic testing shows prolonged clotting time or R time, fresh-frozen plasma or PCC should be administered, as this indicates delayed clot initiation due to factor deficiency or inhibition.³ (Link)
• When maximum clot firmness (MCF) is low with a normal platelet count, fibrinogen concentrate, or cryoprecipitate should be given because this pattern signifies inadequate fibrinogen contribution to the clot.^3,4
• When MCF is low and thrombocytopenia is present, platelet transfusion should be administered because an adequate platelet count is essential for clot reinforcement.^3,5
• When fibrinolysis indicators (e.g., LY30 or ML) are elevated, tranexamic acid (TXA) should be administered, as it inhibits plasmin activation and stabilizes the fibrin clot.⁶

Pharmacologic Therapy: TXA

• TXA should be given early in trauma using a 1 g IV bolus followed by 1 g over 8 hours within 3 hours of injury, because early inhibition of fibrinolysis lowers mortality.⁶ (Link)
• In postpartum hemorrhage (PPH), TXA 1g IV should be given at diagnosis with one repeat dose if bleeding persists.⁷
• TXA 10-15 mg/kg (± infusion) is reasonable in orthopedic and cardiac surgery, because these procedures activate fibrinolysis and TXA reduces transfusion requirements and surgical blood loss.⁶ (Link)

Massive Transfusion Protocols (MTP)

• Indication and Activation (Link)
  • An MTP should be activated when bleeding exceeds four units of RBCs/hour, the patient demonstrates shock unresponsive to crystalloid, or trauma criteria are met.10
  • Rapid, clear communication with the blood bank should occur because coordinated delivery of predefined transfusion packs prevents delays and reduces under-resuscitation.¹⁰
• Early Balanced Resuscitation
  • The initial MTP pack should approximate a 1:1:1 ratio of RBCs, plasma, and platelets, because balanced transfusion prevents dilution of clotting factors and improves survival compared with RBC-heavy strategies.¹⁰
• Ongoing Assessment and Transition to Targeted Therapy
  • After initial stabilization, transfusion should transition to laboratory-guided or viscoelastic-guided therapy, because targeted correction reduces unnecessary product use and accelerates hemostasis.^1,3
  • Hemoglobin, fibrinogen, platelet count, ionized calcium, and viscoelastic parameters should be checked every 20-30 minutes.¹⁰

Special Populations

• Trauma (Link)
  • Trauma patients often arrive in the operating room already coagulopathic, so initial management should assume a high likelihood of fibrinogen depletion, platelet dysfunction, and hyperfibrinolysis even when early laboratory values appear near normal.
  • TXA should be administered within 60 minutes of presentation whenever major trauma is suspected, because early treatment prevents progressive compensated fibrinolysis to fulminant hyperfibrinolysis, which is associated with sharply increased mortality once LY30 exceeds 3-5% on viscoelastic assays.⁶
  • Whole blood should be used when available, as it provides RBCs, platelets, and plasma in physiologic ratios comparable to a 1:1:1 strategy and reduces the time and dilution associated with separate component transfusion.¹ (Link)
  • Temporary permissive hypotension with MAP around 50-60 mmHg may be used in selected penetrating torso trauma without traumatic brain injury, because maintaining lower arterial pressure reduces blood loss until definitive hemorrhage control is achieved.^1,6
  • Ionized calcium should be rechecked every 15-20 minutes during active trauma resuscitation and maintained above 1.1 mmol/L.¹⁰
  • Core temperature should be monitored continuously and maintained above 35-36 °C.¹
  • “Damage-control anesthesia,” with rapid induction, minimal myocardial depressant drugs, and early vasopressor support, should be used during unstable phases, because deep anesthesia and excessive vasodilation exacerbate shock and accelerate the development of coagulopathy.
• Obstetric Hemorrhage (OA summary on PPH Link) (OA summary on transfusion medicine Link)
  • Fibrinogen levels should be measured early in PPH because levels below 200 mg/dL strongly predict progression to severe hemorrhage and the need for massive transfusion or hysterectomy.^5,7
  • TXA should be administered within 3 hours of PPH onset, because early antifibrinolytic therapy significantly reduces death from bleeding.⁷
  • Uterotonics, intrauterine balloon tamponade, and uterine compression sutures should be deployed along hemostatic therapy, because obstetric bleeding is frequently driven by mechanical uterine atony in addition to systemic coagulopathy.⁷
  • Platelets should generally be maintained at or above 75 x 10⁹/L in significant obstetric hemorrhage, because the uteroplacental circulation is highly vascular and more sensitive to both quantitative and qualitative platelet defects.⁴
  • Crystalloid administration should be limited in PPH because early administration of large volumes dilutes clotting factors and platelets.
• Liver Disease (Link)
  • Patients with cirrhosis often have decreased procoagulant proteins but elevated factor VIII and von Willebrand factor, so the INR is not a reliable marker of bleeding risk and should not be used as the sole trigger for plasma transfusion.
  • Viscoelastic tests in cirrhotic patients frequently show near-normal clot initiation but reduced clotting. Firmness, indicating that fibrinogen deficiency or thrombocytopenia are the dominant problems rather than isolated factor deficiency.
  • Fibrinogen should be targeted to levels greater than 180-200 mg/dL for major abdominal surgery in patients with advanced liver disease, because fibrinogen synthesis is impaired and consumption increases quickly with surgical trauma.
  • Platelet transfusion should be considered when the platelet count is less than 50 x 10^{^9/L}; however, for elective procedures, thrombopoietin receptor agonists may be used preoperatively to raise platelet counts and avoid transfusion-related increases in volume and portal pressure.
  • Plasma transfusion should be avoided unless viscoelastic or clinical evidence indicates impaired clot formation, because plasma volume loading increases portal pressure, exacerbates variceal bleeding, and may worsen ascites and pulmonary edema without clearly improving hemostasis.
  • Cryoprecipitate is often preferable to fresh frozen plasma for fibrinogen replacement in cirrhosis because its higher fibrinogen-to-volume ratio reduces the risk of portal hypertension and fluid overload.⁸
• Cardiopulmonary Bypass (CPB)
  • A prolonged CT or R time on viscoelastic testing shortly after protamine suggests factor deficiency or residual heparin effect and should prompt treatment with plasma or additional protamine guided by heparin-sensitive assays.³
  • A low MCF with a normal platelet count usually indicates hypofibrinogenemia after CPB; this pattern should be treated with fibrinogen concentrate or cryoprecipitate.3,5
  • A low MCF, low platelet count, or clear platelet dysfunction should prompt platelet transfusion.^3,4
  • If viscoelastic tracings show prominent fibrinolysis after protamine, antifibrinolytic therapy with TXA should be continued or initiated, as CPD stimulates plasmin activation, and post-protamine fibrinolysis can be an important driver of refractory bleeding.⁶ (Link)
  • TXA should be used routinely in cardiac procedures because CPB induces fibrinolysis and TXA reduces transfusion requirements.⁶
• Patients on Chronic Anticoagulation
  • Patients on DOACs requiring emergent surgery should get drug-specific assays, such as anti-XA levels for factor Xa inhibitors or dilute thrombin time for dabigatran.²
  • Idarucizumab should be used to reverse dabigatran when urgent high-risk surgery is needed, and the dabigatran effect is still present.²
  • Adexanet alfa may be used to reverse apixaban or rivaroxaban in life-threatening bleeding or urgent surgery, but its use should be balanced against cost and a transient degree of rebound hypercoagulability.²
  • When specific reversal agents are unavailable, 4-factor PCC in doses of 25-50 units/kg can be used as an alternative for factor Xa inhibitor-associated bleeding.²
  • In patients with recent coronary stents, the decision to discontinue P2Y12 inhibitors should take into account the type of stent and the time since implantation, as premature discontinuation within the first 1-3 months after stenting greatly increases the risk of stent thrombosis and mortality.² (Link)

Postoperative Management

Postoperative Hemorrhage Surveillance

• Postoperative vital signs should be monitored closely for persistent tachycardia, unexplained hypotension, or rising oxygen requirements, because these may be early indicators of bleeding before overt changes in hemoglobin are apparent.^3,4
• Surgical drains should be assessed at least hourly in the early postoperative period, and sudden increases in bright-red output or a sustained rate above roughly 3 mL/kg/h for several hours should prompt evaluation for re-bleeding and possible re-exploration.⁹
• A point-of-care hemoglobin measurement should be obtained within 1-2 hours after arrival in the recovery area or ICU for high-risk patients, because immediate postoperative hemodilution can mask early anemia or later static laboratory results.^9,10
• Patients who underwent massive transfusion or received large doses of fibrinogen and FXIII intraoperatively should have coagulation parameters and viscoelastic tests repeated every 4-6 hours on the first postoperative day.

Postoperative Correction of Coagulation Abnormalities

• Fibrinogen should be rechecked within several hours postoperatively in patients with major blood loss, and additional cryoprecipitate or fibrinogen concentrate should be administered when levels remain below target thresholds.⁵
• Platelet transfusion should be repeated in patients whose platelet counts fall below 50 x 109/L or whose viscoelastic testing shows inadequate platelet contribution to clot firmness.⁴
• FXIII concentrate should be considered in patients with ongoing diffuse oozing and low FXIII levels, particularly after prolonged surgery or massive transfusion, because FXIII deficiency is often unmasked late and is not reflected in PT or aPTT values.¹

Postoperative Anemia Management

• Intravenous iron should be started early in the postoperative course for patients with iron-deficiency anemia, especially when further blood loss is unlikely.¹
• RBC transfusions should be reserved for hemodynamically stable patients with hemoglobin levels below 7 mg/dL, with higher thresholds in patients with active coronary disease.⁹

Reinitiation of Anticoagulation

• Pharmacologic venous thromboembolism (VTE) prophylaxis with low-dose low-molecular-weight heparin or unfractionated heparin should be initiated once surgical hemostasis is secure, typically within 12-24 hours after surgery, because postoperative patients remain at high risk of VTE due to immobility and systemic inflammation.²
• Full-dose anticoagulation should generally be resumed within 24-72 hours after surgery, depending on bleeding risk and thrombotic indication, as earlier resumption reduces thrombotic events but must be weighed against the risk of re-bleeding at the operative site.²
• Patients who received reversal agents such as andexanet alfa or idarucizumab should be monitored particularly closely for thrombotic complications and have anticoagulation restarted as soon as it is safe.²

Postoperative Analgesia Considerations

• Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided or used cautiously in patients with residual coagulopathy or high bleeding risk, as NSAIDs inhibit platelet function and may increase gastrointestinal and surgical site bleeding.²
• Regional anesthesia and deep peripheral nerve blocks should be planned cautiously postoperatively in patients with fluctuating coagulation profiles, because delayed bleeding into neuraxial or deep fascial compartments can cause serious neurologic or compressive complications.²
• A multimodal analgesic regimen built around acetaminophen, gabapentinoids, low-dose ketamine, and carefully selected regional techniques, when safe, should be favored because this reduces opioid requirements, stabilizes hemodynamics, and indirectly supports adequate coagulation and perfusion.²